Effects of Galvus (Vildagliptin) on Markers of Inflammation in Diabetic Foot Ulcer: A Prospective, Randomized, Double-blind, Placebo-Controlled Pilot Study (Old ID 21121)

Chief Investigator

Interlukin-6 is an established inflammatory marker that has been shown to be increased in individuals with diabetic foot ulcers (DFU). Furthermore, DFU has been referred to as an inflammatory state. Therefore, a reduction in inflammatory markers in this high-risk population is likely to correlate with a corresponding improvement of diabetic foot ulcer healing. We aim to study in this pilot clinical trial the effect of Vildagliptin on regulation of IL-6 and its effects on diabetic foot ulcers healing.

01 Aug 2013 - 31 Oct 2018

N/A